5Weimar C,Diener HC,Alberts MJ,et al.The essenstroke risk score predicts recurrent cardiovascular events:A validation within the reduct ion of atherothrombosisfor cont inued health(reach)registry[J].Stroke,2009,40:350-354.
6Stroke risk in Atrial Fibrillation Working Group.Compari-sion of 12 riskstratification schemes to predict stroke inpatients with nonvalvular atrial fibrillation[J].Stroke,2008,39:1901-1910.
7Independent predictors of stroke in patients with atrial fi-brillation:a systematic review[J].Neurology,2007,69:546-554.
8Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis, 2008, 25 : 26 - 32.
9Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke, 2008, 39:1901 - 1910.
10Taggar JS, Watson T, Lip GY. Can patients with atrial fibrillation be optimally risk stratified for stroke and thromboembolism? Stroke, 2008, 39:e24 - e25.
3Donald M,Thomas JW,Erie PL,et al. Life time risk for development of atrial fibrillation: The framingham heart study [ J ]. Circulation, 2004,110(9) :1042 - 1046.
4Wallentin L, Yusuf S, Ezekowitz MD, et al.. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : anan- alysis of the RE - LY trial[ J ]. Lancet ,2010,376 (9745) :975 - 983.
5The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboem bolism [ J ]. N Eng 1J Med ,2010,363 (26) :2499 - 2510.
6ROCKETAF Study Investigators. Rivaroxaban-once daily,oral,direct factor Xa inhibition compared with vitamin K antagonism for preven- tion of stroke and Embolism Trial in Atrial Fibrillation: rational and design of the ROCKET AF study [ J]. Am Heart J ,2010 ; 159 ( 3 ) : 340. e1 - 347.
7S van Diepen, JA Bakal, FA McAlister, et al. Mortality and read- mission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38047 patients[ J]. Circulation ,2011,124 (3) :289 - 296.
